Stock VRPX VIRPAX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Virpax Pharmaceuticals, Inc. Stock

Equities

VRPX

US9282512063

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:30:01 2024-04-26 EDT 		5-day change 1st Jan Change
3.1 USD +6.22% Intraday chart for Virpax Pharmaceuticals, Inc. -15.76% -3.16%
03-26 Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-15 Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs MT

Financials

Sales 2024 * - Sales 2025 * - Capitalization 3.63M 4.96M
Net income 2024 * -17M -23.24M Net income 2025 * -22M -30.07M EV / Sales 2024 * -
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * -
P/E ratio 2024 *
-0.38 x
P/E ratio 2025 *
-0.38 x
Employees 7
Yield 2024 *
-
Yield 2025 *
-
Free-Float 74.28%
More Fundamentals * Assessed data

Chart Virpax Pharmaceuticals, Inc.

Dynamic Chart

Latest news about Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs MT
Virpax Pharmaceuticals Announces Preliminary Results of Probudurtm Pilot Study with the U.S. Army Institute of Surgical Research CI
Virpax Pharmaceuticals Stockholders Approve Reverse Stock Split Plan; Shares Fall MT
Virpax Pharmaceuticals Announces Leadership Transition CI
Virpax Pharmaceuticals, Inc. Announces CEO Changes CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Virpax Pharmaceuticals Announces Envelta Remains on Track for Trial in Humans Following FDA Review CI
Virpax Names Gerald Bruce as CEO of Novvae Pharmaceuticals Unit MT
Novvae Pharmaceuticals Announces Executive Appointments CI
Virpax Forms New Unit Novvae Pharmaceuticals MT
Virpax Pharmaceuticals, Inc Announces the Formation of Novvae? Pharmaceuticals CI
Virpax Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Virpax Pharmaceuticals, Inc. Files Provisional Patent Application for NSAID Formulation and Method CI
Virpax Pharmaceuticals Files Patent For Envelta Product Candidate MT
More news

Analyst Recommendations on Virpax Pharmaceuticals, Inc.

Analysis-Biotech IPOs to bloom with spotlight on startups with human trial data RE
Maxim Group Initiates Coverage on Virpax Pharmaceuticals With Buy Rating, $4 Price Target MT
More recommendations

Press releases Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals Reports 2023 Year-End Results BU
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price AQ
Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price BU
Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc. BU
Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research BU
More press releases

News in other languages on Virpax Pharmaceuticals, Inc.

Altasciences von Virpax ausgewählt, um die Entwicklung eines neuen Medikaments zur Verhinderung der Ausbreitung von grippeähnlichen Viren zu unterstützen
Altasciences choisi par Virpax pour soutenir le développement d'un nouveau médicament pour empêcher la propagation de virus apparentés à la grippe
Virpax Pharmaceuticals étend ses droits de développement et de commercialisation d'AnQlar™ par un accord de licence mondial
Virpax Pharmaceuticals erweitert seine Entwicklungs- und Vermarktungsrechte an AnQlar™ mit weltweiter Lizenzvereinbarung
Altasciences a été choisie par Virpax Pharmaceuticals, Inc. pour mener les premiers essais cliniques chez l'humain portant sur l'Epoladerm™ en vue de traiter les douleurs chroniques associées à l'arthrose du genou
More news

Quotes and Performance

1 day+6.22%
1 week-15.76%
Current month-27.25%
1 month-20.10%
3 months-0.03%
6 months-58.11%
Current year-3.16%
More quotes

Highs and lows

1 week
2.85
Extreme 2.85
3.65
1 month
2.85
Extreme 2.85
4.27
Current year
2.54
Extreme 2.543
5.48
1 year
2.40
Extreme 2.402
11.77
3 years
2.40
Extreme 2.402
360.00
5 years
2.40
Extreme 2.402
360.00
10 years
2.40
Extreme 2.402
360.00
More quotes

Managers and Directors - Virpax Pharmaceuticals, Inc.

Managers TitleAgeSince
Jeffrey Gudin FOU
 Founder 58 16-12-31
Gerald Bruce CEO
 Chief Executive Officer 68 17-07-31
Vinay Shah DFI
 Director of Finance/CFO 62 23-06-19
Members of the board TitleAgeSince
Gerald Bruce CEO
 Chief Executive Officer 68 17-07-31
Jeffrey Gudin FOU
 Founder 58 16-12-31
Barbara A. Ruskin BRD
 Director/Board Member - 23-03-23
More insiders

Quotes

Date Price Change Volume
24-04-26 3.1 +6.22% 5,246
24-04-25 2.918 -7.94% 8,353
24-04-24 3.17 +0.32% 4,665
24-04-23 3.16 -4.24% 11,455
24-04-22 3.3 -10.33% 16,065

Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm

More quotes

Company Profile

Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company. The Company is focused on developing novel and proprietary drug delivery systems across various pain indication. Its drug-delivery systems and drug-releasing technologies being developed are focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system (CNS) disorders to enhance patients’ quality of life. Its portfolio consists of multiple preclinical stage product candidates: Epoladerm, Probudur, Envelta, AnQlar and NobrXiol. Probudur is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain. Envelta is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. The NobrXiol is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy.
Sector
Biotechnology & Medical Research
Calendar
2024-05-13 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.1 USD
Average target price
20 USD
Spread / Average Target
+545.16%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
VIRPAX PHARMACEUTICALS, INC. Stock Virpax Pharmaceuticals, Inc.
-3.16% 3.63M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. VRPX Stock